Page last updated: 2024-12-06

1-hydroxy-2(1h)-pyridinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Hydroxy-2(1H)-pyridinone, also known as 2-hydroxypyridin-1(2H)-one, is a heterocyclic compound that exhibits a wide range of biological activities. It is of interest for its potential applications in medicinal chemistry, particularly as a chelating agent for metal ions. The compound has shown promise as a drug candidate for treatment of various diseases, including cancer, Alzheimer's disease, and bacterial infections. Its synthesis involves various methods, including the reaction of 2-hydroxypyridine with an oxidizing agent, such as hydrogen peroxide. Research on 1-hydroxy-2(1H)-pyridinone focuses on its chelating properties, its ability to inhibit enzyme activity, and its potential as a drug candidate for various diseases.'

1-hydroxy-2(1H)-pyridinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID69975
CHEMBL ID81398
CHEMBL ID3898657
SCHEMBL ID112186
SCHEMBL ID40240
MeSH IDM0543410

Synonyms (78)

Synonym
AC-5082
CHEMBL81398 ,
2-hydroxypyridine 1-oxide
LS-13037
2-hydroxypyridine-n-oxide
2-pyridinol-1-oxide
AC-907/25014064
pyridin-2-ol 1-oxide
inchi=1/c5h5no2/c7-5-3-1-2-4-6(5)8/h1-4,8
pyridinium,1,2-dihydroxy-,1-hydroxide,inner salt
13161-30-3
nsc-406972
nsc406972
2-pyridinol, 1-oxide
AC-907/25004409
NCIOPEN2_003773
2-pyridinol 1-oxide, >=98.0% (n)
1-hydroxypyridin-2-one
FT-0693752
2-hydroxypyridine n-oxide
H0672
1-hydroxy-2-pyridone
2-pyridinol n-oxide
bdbm50057413
AKOS000121480
AKOS006273363
1-hydroxy-2-(1h)-pyridone
2-hydroxypridine-n-oxide
unii-yo3915897s
n-hydroxyl-2-pyridone
yo3915897s ,
822-89-9
2(1h)-pyridinone, 1-hydroxy-
hydroxypyridinone
hydroxyl-2-pyridone
einecs 212-506-0
oxypyrion
2-hydroxypyridin-1-ium-1-olate
2-pyridinol 1-oxide
pyridinol, 1-oxide
FT-0636819
AM20061694
hydroxypyridinone [inci]
n-hydroxy-2-pyridone
1-hydroxy-2(1h)-pyridone
1-hydroxy-2(1h)-pyridinone
1-hydroxy-1,2-dihydropyridin-2-one
CS-M0760
n-hydroxy-2-pyridon
1-hydroxypyridine-2(1h)-one
n-hydroxy-pyridone
n-hydroxypyridone
SNUSZUYTMHKCPM-UHFFFAOYSA-N
SCHEMBL112186
SCHEMBL40240
DTXSID70231622
2-hydroxy-pyridine-n-oxide
2-hydroxy-pyridine n-oxide
2-hydroxypyridine-1-oxide
2-hydroxy-pyridin-1-oxide
JVHZMYAXZUIZKS-UHFFFAOYSA-N
2-hydroxypyridin-1-oxide
mfcd00006195
SY019070
oxy-pyrion? 1-hydroxy-2(1h)-pyridinone speciality chemicals
Q-101944
2(1h)-pyridinone, hydroxy-
CHEMBL3898657 ,
bdbm50205814
CS-0221893
AS-17882
BCP13006
Q27294618
O10803
EN300-100484
2-HYDROXYPYRIDINE1-OXIDE ,
EN300-21097
Z1198152560

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Finally, to improve its oral bioavailability, 3,4,3-LI(1,2-HOPO) was coformulated with a proprietary permeability enhancer, leading to a notable increase in oral bioavailability of the compound."( Biodistribution of the multidentate hydroxypyridinonate ligand [(14) C]-3,4,3-LI(1,2-HOPO), a potent actinide decorporation agent.
Abergel, RJ; An, DD; Bunin, DI; Chang, PY; Choi, TA; Colas, C; Dabbs, JE; Endsley, AN; Morales-Rivera, JA; Shinn, WM; Villalobos, JA, 2015
)
0.42
" We developed an in vitro acellular assay to predict in vivo bioavailability of actinides and improve medical handling of the victims."( A quick and simple in vitro assay to predict bioavailability of actinides following accidental exposure.
Angulo, JF; Bohand, S; Griffiths, NM; Van der Meeren, A, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TyrosinaseHomo sapiens (human)IC50 (µMol)725.00000.02304.459310.0000AID1331360; AID1331361
TyrosinaseHomo sapiens (human)Ki128.00001.70004.73339.1000AID1331359; AID1611943
Lethal factorBacillus anthracisIC50 (µMol)5,000.00000.09702.85976.0000AID1187450
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)IC50 (µMol)353.00005.00005.00005.0000AID1893771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusKic1.80000.70002.30004.3000AID1611946
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID29379Acid dissociation constant (pKa2) was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID1187450Binding affinity to anthrax lethal factor2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Exploring the influence of the protein environment on metal-binding pharmacophores.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID28931Logarithm of cumulative stability constant was determined1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1893771Inhibition of recombinant human QC using H-Gln-AMC hydrobromide as fluorogenic substrate incubated for 6 hrs by fluorometric microplate reader analysis2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPĪ± Checkpoint.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1331357Competitive inhibition of mushroom TyM1 using L-DOPA as substrate by Lineweaver-Burk reciprocal plot analysis2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
2-Hydroxypyridine-
AID1611943Inhibition of human tyrosinase2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID1717716Competitive inhibition of mushroom tyrosinase using L-DOPA as substrate by dixon-plot analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1331361Inhibition of tyrosinase in human MNT1 cells assessed as suppression of melanin biosynthesis measured after 96 hrs2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
2-Hydroxypyridine-
AID1331363Competitive inhibition of Streptomyces antibioticus TyB3 preincubated for 5 mins followed by addition of L-DOPA as substrate measured for 5 mins by spectroscopic method2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
2-Hydroxypyridine-
AID1331362Cytotoxicity against human MNT1 cells2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
2-Hydroxypyridine-
AID1611946Competitive inhibition of Agaricus bisporus tyrosinase2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID1331359Inhibition of recombinant human tyrosinase expressed in baculovirus infected Sf9 cells assessed as diphenolase activity using L-DOPA as substrate by UV-vis spectrophotometry2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
2-Hydroxypyridine-
AID1331360Inhibition of tyrosinase in human MNT1 cell lysate pretreated prior to addition of L-DOPA as substrate measured after 3 hrs2017ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1
2-Hydroxypyridine-
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (3.70)18.2507
2000's2 (7.41)29.6817
2010's20 (74.07)24.3611
2020's4 (14.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]